Harmony Biosciences Revenue and Competitors

Claim your profile

Location

#8524

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Harmony Biosciences's estimated annual revenue is currently $36.4M per year.(i)
  • Harmony Biosciences received $200.0M in venture funding in March 2019.
  • Harmony Biosciences's estimated revenue per employee is $148,673
  • Harmony Biosciences's total funding is $1.1B.

Employee Data

  • Harmony Biosciences has 245 Employees.(i)
  • Harmony Biosciences grew their employee count by 17% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.6M10-33%N/AN/A
#2
$3.4M2210%N/AN/A
#3
$4.3M673%N/AN/A
#4
$5.4M3525%N/AN/A
#5
$8.4M5413%N/AN/A
#6
$2.2M28-32%$157.5MN/A
#7
$2M138%N/AN/A
#8
$29.5M19012%N/AN/A
#9
$3.7M24-17%N/AN/A
#10
$58.1M375-2%N/AN/A

Patients are at the beginning, middle, and heart of all we do. Harmony Biosciences, LLC, is a privately-owned biopharmaceutical company. The company was established in October 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. Harmony Biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.

keywords:N/A

$1.1B

Total Funding

245

Number of Employees

$36.4M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Harmony Biosciences News

2022-04-20 - Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Expected to Announce Earnings of $0.25 Per Share. Posted by admin on Apr 23rd, 2022.

2022-04-17 - HARMONY BIOSCIENCES ANNOUNCES DATE OF FIRST ...

Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon...

2022-04-17 - Jack Nielsen Sells 4195 Shares of Harmony Biosciences ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) Director Jack Nielsen sold 4,195 shares of the company's stock in a...

2021-10-26 - Harmony Biosciences Announces Date of Third Quarter 2021 Financial Results

PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it wil ...

2021-10-21 - Harmony Biosciences : to be Added to the S&P SmallCap 600® Index

PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it wil ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$46.2M3089%N/A
#2
$106.3M31513%N/A
#3
$71.8M35714%N/A
#4
$139.2M38417%N/A
#5
$6.5M3865%$446.4M

Harmony Biosciences Funding

DateAmountRoundLead InvestorsReference
2017-10-09$270.0MUndisclosedArticle
2019-03-14$200.0MUndisclosedCR Group LPArticle